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Abstract
Background: Copy number variants (CNVs) have been linked to neurodevelopmental disorders such as intellectual
disability (ID), autism, epilepsy and psychiatric disease. There are few studies of CNVs in patients with both ID and
epilepsy.
Methods: We evaluated the range of rare CNVs found in 80 Welsh patients with ID or developmental delay (DD),
and childhood-onset epilepsy. We performed molecular cytogenetic testing by single nucleotide polymorphism
array or microarray-based comparative genome hybridisation.
Results: 8.8 % (7/80) of the patients had at least one rare CNVs that was considered to be pathogenic or likely
pathogenic. The CNVs involved known disease genes (EHMT1, MBD5 and SCN1A) and imbalances in genomic
regions associated with neurodevelopmental disorders (16p11.2, 16p13.11 and 2q13). Prompted by the observation
of two deletions disrupting SCN1A we undertook further testing of this gene in selected patients. This led to the
identification of four pathogenic SCN1A mutations in our cohort.
Conclusions: We identified five rare de novo deletions and confirmed the clinical utility of array analysis in patients
with ID/DD and childhood-onset epilepsy. This report adds to our clinical understanding of these rare genomic
disorders and highlights SCN1A mutations as a cause of ID and epilepsy, which can easily be overlooked in adults.
Keywords: Array comparative genomic hybridization, Intellectual disability, Epilepsy, Copy number variation, SCN1A
Background
Copy number variants (CNVs; chromosomal deletions and
duplications) have been identified as significant aetiological
factors in a range of neurodevelopmental disorders includ-
ing intellectual disability (ID) [1], autism [2], epilepsy [3]
and psychiatric disease [4]. The detection of a causative
CNV in a patient is valuable for genetic counselling and, in
some cases, guiding clinical management. The observation
of a rare chromosomal abnormality in a patient with a rare
neurological phenotype has occasionally been the vital clue
leading to the identification of genes and pathways critical
to brain development [5, 6]. A limited number of previous
genome-wide CNV studies have focused on patients with
both epilepsy and ID [7–10]. We set out to investigate the
rare CNVs present in a series of 80 patients with ID/devel-
opmental delay (DD) and childhood-onset epilepsy. Our
aims were: to determine the frequency of pathogenic CNVs
in the cohort; to define the clinical features of patients
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carrying pathogenic CNVs; to identify any sub-groups of
patients particularly enriched for pathogenic CNVs; and to
highlight candidate genes for epilepsy and ID/DD.
Methods
Study subjects
Participants were recruited between 2010 and 2014. Par-
ticipants were 80 unrelated patients (49 adults and 31
children) identified through medical genetics, learning
disability and paediatric neurology clinics around Wales
(see Additional file 1: Table S1 for further demographic
information). Participants lacked a molecular diagnosis
and had not previously undergone high resolution
genome-wide cytogenetic analysis (<1 Mb resolution).
The majority of participants had previously been
tested by karyotype (61/80) combined with additional
cytogenetic and molecular tests (Additional file 1:
Table S2). Patients with known significant congenital
brain malformations were excluded (e.g. malforma-
tions of cortical development, porencephaly, holopro-
sencephaly or intracerebral vascular malformations).
CNV rates in the general population were estimated
from 929 control subjects derived from the Well-
come Trust Case Control Consortium 2 National
Blood Donors Cohort [11]. These were blood donors
recruited by UK Blood Services and are therefore similar
in ethnic origin to our mostly white British cohort. Con-
trols were genotyped on Illumina OmniExpress single nu-
cleotide polymorphism (SNP)-arrays.
Ethics approval and consent to participate
The study was approved by the Research Ethics
Committee for Wales (09/MRE09/51). Informed con-
sent for testing and publication was obtained from
all participants (or their parents/legal guardians).
Microarray analysis
Genomic DNA was extracted from blood (n = 73) or
saliva (n = 7). Samples were tested on one of three
platforms: (i) Illumina610-Quad SNP-array (n = 20);
(ii) Illumina OmniExpress SNP-array (n = 36); or (iii)
microarray-based comparative genomic hybridization
(array CGH) using a BlueGnome CytoChip ISCA
8x60k v2.0 array (n = 24). Validation testing was per-
formed by fluorescent in situ hybridisation, multiplex
ligation-dependent probe amplification (MLPA) or by
testing on a second array platform. The method for
identifying CNVs depended on the array platform.
SNP-array data was called using PennCNV [12].
Called CNVs were filtered by probe number (10 or
more) and gene content (at least one). We excluded
CNVs which had 50 % or greater overlap with a CNV in
the control cohort. However, for key genomic regions
known to harbour recurrent CNVs associated with
neurodevelopmental disorders which demonstrate incom-
plete penetrance (1q21.1, 15q11.2, 15q13.3, 16p11.2 and
16p13.11) we allowed CNVs to be present at low fre-
quency in controls (<1 %). Analysis focused on deletions
and duplications larger than 100 kb and 250 kb respect-
ively (50 kb for disease regions). Array CGH data was
referenced against same sex control DNA (Promega) and
analysed using Illumina BlueFuse Multi (v3.1) software,
with data filtered on consecutive probes (3 or more) and
size (as above). Imbalances detected by array CGH were
interpreted by comparison with data from the Database
of Genomic Variants, International Standards for Cyto-
genomic Arrays consortium and local laboratory data.
Coordinates are based on hg19/GRCh37. Statistical
comparisons were made using Fisher’s exact test calcu-
lated with an online tool [13]. Parents and additional
family members were analysed, where available, to de-
termine if a CNV had arisen de novo or segregated with
disease in a family. We assessed the clinical significance
of CNVs based on their size, type, inheritance and
whether they contained known disease genes. We were
guided by the approach set out in previous publications
[7, 14]. Based on this assessment some CNVs were an-
notated as ‘pathogenic’ (e.g. a de novo deletion of a
proven disease gene/region) or ‘likely pathogenic’ (e.g.
large CNVs containing genes/regions previously linked
to disease). Other CNVs were considered to be of
unknown significance.
SCN1A gene testing
A subgroup of patients was tested for intragenic SCN1A
mutations. Sequencing of the complete coding region
and flanking sequence of the gene was performed by
bidirectional Sanger sequencing (n = 4) or by targeted
next-generation sequencing (NGS) (n = 11). Sequencing
(Sanger or NGS) covered all the coding sequence of
SCN1A along with 20 bp of flanking intron or untrans-
lated region (UTRs). Sequencing did not cover the
promoter, deep intronic regions or the rest of the UTRs.
In silico analysis of detected variants included PhyloP
[15], SIFT [16], Grantham distance [17], PolyPhen-2 [18]
and CADD [19]. We also searched the Exome Aggrega-
tion Consortium (ExAC) database [20], dbSNP [21], Clin-
Var [22] and an SCN1A mutation-specific database [23].
Nucleotide and protein positions are based on NCBI Ref-
erence Sequences NM_001165963.1 and NP_001159435.1
respectively [24].
Results and discussion
The 80 patients had a range of epilepsy phenotypes in-
cluding epileptic encephalopathy (EE, n = 25), non-
lesional focal epilepsies (n = 22), and genetic generalised
epilepsy with ID (GGE-ID, n = 22) (Table 1). In the re-
mainder, the epilepsy phenotype was unclassified or
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unknown. We found 22.5 % (18/80) of the cohort carried
at least one rare CNV (Table 2). Three patients had
more than one rare CNV. The average size of the
CNVs was 647 kb (median 488 kb). We identified 8
CNVs considered to be likely (n = 3) or clearly patho-
genic (n = 5) (Table 2). One patient (R660) had one
clearly and one likely pathogenic CNV. This meant 7
(8.8 %) of our patients had pathogenic or likely patho-
genic CNVs. Additional rare variants of uncertain
clinical significance (VUS) were present in 11 further
patients. We compared the frequency of CNVs in patients
and controls. We found that large (>500 kb) low
frequency (<1 %) genic CNVs were marginally more com-
mon in patients (13 %, 10/80) compared with controls
(11 %, 105/929). However, this difference was not statisti-
cally significant (P = 0.71). The majority of patients had
previously been tested by karyotype which will have
depleted larger CNVs from the cohort.
Pathogenic CNVs
The five clearly pathogenic CNVs were all de novo dele-
tions. We found a de novo 127 kb deletion of 2q23.1 in a
woman with moderate ID, mildly dysmorphic facial fea-
tures (long face, thin upper lip, slightly upslanting palpe-
bral fissures, long nose) and seizures. The deletion
disrupted the first two non-coding exons of the MBD5
gene. MBD5 encodes a member of the methyl-CpG-
binding domain family. The MBD5 protein binds to
methylated DNA and is thought to regulate gene expres-
sion by controlling chromatin modification [25]. Dele-
tions of the 5′- UTR of MBD5 result in reduced
expression of the gene [26]. Common clinical features in
MBD5 patients include ID/DD, seizures, language im-
pairment, microcephaly, mild craniofacial dysmorphism
and autism spectrum disorders (ASD) [26–28]. Interest-
ingly, patients with CNVs confined to the 5′-UTR (like
R911) have phenotypes similar to patients with larger
2q23.1 deletions. This highlights the critical impact of
non-coding sequence at the locus [29].
We observed a de novo 182 kb deletion at 9q34.3 in-
volving EHMT1 in an adult male (R660) with moderate-
to-severe ID, dysmorphic features (hypertelorism, mid
face hypoplasia, prognathism), aggressive behaviour, aut-
istic features, depression and epilepsy. Deletions at 9q34
involving EHMT1 are responsible for Kleefstra syndrome
[30]. EHMT1 encodes a histone methyltransferase in-
volved in transcriptional repression. EHMT1 is known
to interact with MBD5 and they work together to regu-
late gene expression [25]. Characteristic features of
Kleefstra syndrome include ID/DD, microcephaly, psy-
chiatric disorders, severe behavioural problems, dys-
morphic features, hypotonia, heart defects and seizures
[31]. In addition to truncating EHMT1 the 9q34 deletion
involved the adjacent CACNA1B gene. CACNA1B en-
codes a subunit of a voltage-dependent calcium channel
expressed on neurons. Mutations in other N-type
voltage-dependent calcium channel subunits have been
linked to a wide range of paroxysmal disorders including
periodic paralysis [32], familial hemiplegic migraine [33],
myoclonus-dystonia syndrome [34], childhood absence
epilepsy [35] and idiopathic generalized epilepsy [36].
Therefore, it is possible that haploinsufficiency of CAC-
NA1B may have contributed to the patient’s epilepsy
phenotype. Patient R660 also had a paternally-inherited
1.3 Mb duplication involving the FHIT gene (considered
to be likely pathogenic). The FHIT gene is a member of
the histidine triad gene family. FHIT encodes diadeno-
sine 5′,5‴-P1,P3-triphosphate hydrolase, an enzyme in-
volved in purine metabolism. Rare CNVs involving FHIT
have previously been described in autism [37, 38]. R660
carried a third rare CNV, a maternally-inherited 465 kb
deletion at 3p22.1 involving ULK4. ULK4 encodes a
serine/threonine kinase. Expression of the ULK4 gene is
neuron-specific and developmentally regulated [39]. This
third CNV was considered to be a VUS, although dele-
tions in ULK4 have recently been reported as a potential
risk factor for schizophrenia [39].
The third clearly pathogenic CNV was a de novo
603 kb 16p11.2 deletion in a girl with mild DD, ASD
and infantile spasms (seizure free following treatment).
Seizures are a common feature of 16p11.2 deletion syn-
drome along with ASD, ID/DD, psychiatric disease and
increased risk of obesity [40, 41]. The reciprocal duplica-
tions at 16p11.2 locus have also been associated with
epilepsy including infantile spasms [7, 42]. The last two
Table 1 Epilepsy syndromes in the cohort at recruitment
Syndrome Number
Epileptic encephalopathy (EE)
Lennox-Gastaut syndrome 9
Dravet syndrome 3
West syndrome 2
Myoclonic astatic epilepsy 2
Epilepsy of infancy with migrating focal seizures 2
Ohtahara syndrome 1
Epilepsy with continuous spikes and waves during sleep 1
Unclassified EE with onset in infancy 5
Genetic generalised epilepsy with intellectual disability (GGE-ID)
Myoclonic epilepsy 3
Progressive myoclonic epilepsy 1
Other GGE-IDs 18
Non-lesional focal epilepsies 22
Unclassified epilepsy 2
Unknown 9
Total 80
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Table 2 Rare CNVs detected in 80 patients with ID/DD and epilepsy
Subject Age Sex Clinical features Seizure
onset
Syndrome Seizure
types
Cytoband CNV
Type
Coordinates Size
(Kb)
Tests Status Interpretation Genes
R125 10 m F Severe DD, cleft palate 3 m EIMFS FE, EBCS,
CSE
2q24.3 Del 163823021–
167958723
4,136 c/f DN Path SCN3A, SCN2A, SCN1A,
SCN9A, SCN7A & 8 others
R351 15y M Moderate DD, poor
coordination, joint
contractures, mildly
dysmorphic
3 m Dravet FS, GTCS,
CSE, M
2q24.3 Del 166842637–
166918932
76 c/d DN Path SCN1A
R404 7y F Mild DD, ASD 8 m West IS, Abs 16p11.2 Del 29595483–
30198151
603 b/e,f DN Path DOC2A, KIF22, MAPK3,
PRRT2, QPRT, SEZ6L2 & 24 others
R660 21y M Mod-severe ID,
challenging behaviour,
ASD, depression,
dysmorphic
8 m GGE-ID Abs, M,
FDS,
EBCS
9q34.3 Del 140707889–
140890373
182 b/e DN Path CACNA1B, EHMT1
3p14.2 Dup 59736299–
61023355
1,287 b/e Pat Likely FHIT
3p22.1 Del 41359533–
41824555
465 b/e Mat VUS ULK4
R911 22y F Mod ID, small head, mildly
dysmorphic
10y FE FDS, GTCS 2q22.3 Del 148691873–
148818437
127 b/e DN Path MBD5, ORC4
R913 20y M Mod-severe ID, challenging
behaviour, ASD
10 m FE FS, FDS,
EBCS
16p13.11 Dup 15512574–
16262571
750 b/e Mat Likely ABCC1, C16orf45, FOPNL,
KIAA0430, MIR484, MYH11, NDE1
R345 27y F Mild ID, dysmorphic <6y GGE-ID M, Abs,
GTCS
2q13 Del 111392259–
113094793
1,703 b/e Pat Likely BUB1, BCL2L11, ANAPC1,
MERTK, FBLN7 & 5 others
R58 26y F Severe ID, scoliosis <8y GGE-ID At, Abs, M 1q21.1 Dup 145625979–
145723645
98 a/e Mat VUS CD160, RNF115
R74a 51y F Mild-mod ID, depression 3 m FE FS, FE,
EBCS
1p21.1 Del 104167778–
104297867
130 a/e U VUS AMY1A, AMY1B, AMY1C, AMY2A
R101 32y M ID, seizures <16y U U 11q22.3 Del 109173027–
109325299
152 b/e Pat VUS C11orf87
R198 19y M Severe ID, ASD, mild right
hemiparesis
7 m LGS FE, IS, Abs,
NCS, GTCS,
At, FDS
Xq28 Del 150589930–
150811921
222 c/nd U VUS PASD1
R528 23y M Severe ID, challenging
behaviour, ASD, dysmorphic,
regression
11y FE FE, Abs 15q13.3 Dup 32019919–
32514341
494 b/e U VUS CHRNA7
R605 41y M ID, seizures <16y U U 15q11.2 Dup 22383292–
23272733
889 b/e Pat VUS CYFIP1, NIPA1, NIPA2,
TUBGCP5 & 8 others
8p23.1 Del 11713852–
12204679
491 b/e Mat VUS CTSB, FAM66D, FAM86B1,
USP17L2, ZNF705D & 6 others
R622a 28y F Moderate ID, challenging
behaviour
6 m GGE-ID IS, GTCS,
M
18p11.22 Dup 10042023–
10581304
539 b/e Mat VUS APCDD1, NAPG
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Table 2 Rare CNVs detected in 80 patients with ID/DD and epilepsy (Continued)
R650 21y M Mild ID, thin habitus,
depression
18 m GGE-ID Abs, M,
GTCS
15q13.3 Dup 32029693–
32514926
485 a/nd U VUS CHRNA7
15q14 Del 34700297–
34807869
108 a/nd U VUS GOLGA8A
R786 9y M Moderate DD, Leg
hypertonia, dystonia
2y GGE-ID
(M)
M, Abs, At 21q21.3 Del 27715263–
27955385
240 a/e Mat VUS CYYR1
R931 15y F Severe DD, ASD,
dysmorphic, microcephaly
12y GGE-ID GTCS 7q11.22 Del 71815170–
72305671
491 b/e Pat VUS CALN1, MIR4650-1,
MIR4650-2, SBDSP1, TYW1B
R981 5y F Severe DD, regression,
ASD, leg hypertonia
1w GGE-ID Abs, At,
M, T
3p26.3 Dup 726675-
1301830
575 c/nd U VUS CNTN6
Age (at recruitment) and seizure onset in y(ears), m(onths) or w(eeks). Clinical features: ID intellectual disability, DD, developmental delay, ASD autism spectrum disorder
Syndrome, electroclinical syndrome or main epilepsy type at recruitment: Dravet, Dravet syndrome; EIMFS, epilepsy of infancy with migrating focal seizures: FE focal epilepsy, GGE-ID, genetic generalised epilepsy with
ID, LGS Lennox-Gastaut syndrome, U unknown, West West syndrome
Seizure types: Abs absence, At atonic, CSE convulsive status epilepticus, EBCS evolution to bilateral or convulsive seizures, FDS focal dyscognitive seizures, FS febrile seizures, GTCS generalised tonic-clonic seizures,
IS infantile spasms, M myoclonic, NCS non-convulsive status epilepticus, T tonic, seizure type at presentation is underlined (when known)
CNV type, Dup(lication) or Del(eletion). Coordinates, chromosome position of first/last abnormal probes based on hg19/GRCh37. Tests, primary array/confirmation method: (a) Illumina610-Quad SNP-array, (b) Illumina
OmniExpress SNP-array, (c) BlueGnome CytoChip array CGH, (d) quantitative PCR, (e) Illumina Exome BeadChip or custom Illumina SNP array, (f) fluorescence in situ hybridization, and (nd) not done. Status: DN, de novo;
inherited Pat(ernally); Mat(ernally) or U(nknown). Interpretation (of clinical significance): Path(ogenic); Likely, likely pathogenic; VUS, variant of uncertain significance
aPatients R622 and R74 had pathogenic SCN1A mutations which suggests these two CNVs are likely to be benign
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clearly pathogenic CNVs were both de novo deletions at
2q24.3: one was 76 kb in size and deleted exons 4 to 28
of the SCN1A gene; the other was 4.1 Mb and deleted
13 genes including SCN1A. SCN1A encodes a voltage-
gated sodium channel which is essential for the gener-
ation and propagation of action potentials in neurons.
Mutations in SCN1A cause a spectrum of seizure disor-
ders including familial febrile seizures, generalised epi-
lepsy with febrile seizures plus and Dravet syndrome
(severe myoclonic seizures of infancy) [43–45]. Typical
features of these disorders are seizure onset in infancy
with fever sensitivity. Severe manifestations of SCN1A-
related disease include pharmacoresistant seizures, ID/
DD, ataxia and autistic behaviour [46, 47]. Patient R125,
who had the larger of the two deletions, had a severe
phenotype with poor seizure control, severe DD and a
cleft palate. These additional features may be due to
haploinsufficiency of other genes in the region. The dele-
tion in R125 included SCN2A, SCN3A and SCN9A. All
three of these genes encode voltage-gated sodium chan-
nels which have been linked to epilepsy [48–50]. The pa-
tient’s epilepsy phenotype was considered to be epilepsy
of infancy with migrating focal seizures (EIMFS). A
number of patients with 2q24.3 deletions and EIMFS
-like phenotypes have recently been reported [51, 52].
Patient R351, who had the smaller of the 2q24.3 dele-
tions, had previously undergone SCN1A sequencing
which had not detected their multi-exon deletion. This
highlights that DNA sequencing alone is insensitive to
CNVs and that dose-sensitive techniques (e.g. array
CGH or MLPA) are required to detect a significant pro-
portion of SCN1A mutations [53].
Two further likely pathogenic CNVs were found. One
was a paternally-inherited 1.7 Mb deletion of 2q13 in a
female patient (R345) with mild ID, small ventricular
septal defect, facial dysmorphism (long face, retrognath-
ism, broad nasal root, hypertelorism, mild facial asym-
metry) and epilepsy. Deletions at 2q13, similar to the
one found in patient R345 have been reported in other
patients with DD/ID [54, 55]. Common manifestations
include facial dysmorphism, autistic features, seizures
and cardiac malformations. Previously reported 2q13 de-
letions have been inherited from an apparently normal
parent, consistent with incomplete penetrance. Interest-
ingly, the father of R345 shares similar facial features,
but has no history of ID or epilepsy. The third likely
Table 3 SCN1A mutations in the cohort
Subject R622 R74 R710 R769
Age 28y 51y 24y 3y
Sex F F F F
Clinical features Moderate ID,
challenging behaviour
Mild-mod ID,
depression
Moderate ID, ataxia,
stroke-like episodes
Mod-severe DD,
poor coordination
Seizure onset 6 m 3 m 6 m 5d
Syndrome GGE-ID FE PME CSWS
Seizure types IS, GTCS, M FS, FE, EBCS C-CSE, M, FDS, EBCS T, GTCS, CSE, FE,
At, Abs, M
Genomic coordinates Chr2 g.166915177 _166915180dup Chr2 g.166915162 G > A Chr2 g.166913001 G > C Chr2 g.166848780 C > T
cDNA c.283_286dup c.301C > T c.393C > G c.5005G > A
Protein p.Gly96Glufs*24 p.Arg101Trp p.Ser131Arg p.Ala1669Thr
Inheritance De novo De novo Segregates with
phenotype
De novo
PhyloP - 0.91 (highly conserved) 0.89 (highly conserved) 0.86 (highly conserved)
Grantham distance - 101 (moderate) 110 (moderate) 58 (small)
SIFT - 0 (deleterious) 0.02 (deleterious) 0 (deleterious)
PolyPhen-2
(HumVar)
- 0.982 (probably damaging) 0.368 (benign) 1 (probably damaging)
CADD
(PHRED-scaled)
- 34 (top 0.1 %) 22.3 (top 1 %) 26.1 (top 1 %)
ExAC frequency 0 0 0 0
dbSNP - rs121917965 - -
Age (at recruitment) and seizure onset in y(ears), m(onths) or d(ays). Clinical features: ID intellectual disability, DD developmental delay
Syndrome, electroclinical syndrome or main epilepsy type at recruitment: CSWS, epilepsy with continuous spikes and waves during sleep; FE focal epilepsy,
GGE-ID genetic generalised epilepsy with ID, PME progressive myoclonic epilepsy
Seizure types: Abs absence, At atonic, C clonic, CSE convulsive status epilepticus, EBCS evolution to bilateral or convulsive seizures, FDS focal dyscognitive seizures,
FS febrile seizures, GTCS generalised tonic-clonic seizures, IS infantile spasms, M myoclonic, T tonic, seizure type at presentation is underlined. Coordinates are
based on hg19/GRCh37. Nucleotide and protein reference sequences were NM_001165963.1 and NP_001159435.1
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pathogenic CNV was a maternally-inherited 750 kb
duplication of 16p13.11 in a man with mild ID, ASD, sei-
zures and a history of aggressive episodes. We consid-
ered the 16p13.11 duplication to be likely contributory
as there was a family history of childhood epilepsy in the
patient’s mother and a maternal uncle (untested). Dele-
tions in the 16p13.11 region are clear risk factors for
neurodevelopmental disorders including epilepsy [3, 56].
There is also evidence that duplications at 16p13.11 pre-
dispose to neurodevelopmental disorders (ASD, schizo-
phrenia and ID) [57–60] and have been reported in
patients with epilepsy [61]. Several further CNVs at gen-
omic ‘hot spots’ were observed (duplications at 1q21.1,
15q11.2 and 15q13.3). These duplications were all inher-
ited from unaffected parents and overlapped CNVs in
the control cohort. They were therefore considered to
be VUS. It remains possible that some of these VUS have
contributed to disease risk. For example, there is evi-
dence that CHRNA7 duplications may subtly increase
the risk of neurodevelopmental disorders including ID
[62]. However, further large-scale epidemiological stud-
ies are required to fully define these risks. Among the
non-‘hotspot’ CNVs of uncertain significance we found a
575 kb duplication involving the first 4 exons of CNTN6.
This duplication was identified in a 5-year-old girl with
severe DD, ASD, bilateral lower limb hypertonia and
early-onset seizures. CNTN6 is an interesting candidate
gene for neurodevelopmental disorders as it encodes a
neural adhesion molecule that operates in the formation,
maintenance and plasticity of neuronal networks. In
addition, CNVs involving CNTN6 have been reported in
patients with DD/ID and autistic features [2, 63–65].
SCN1A mutations
Struck by finding two deletions involving SCN1A we rea-
lised that this key monogenic cause of epilepsy had not
been extensively pre-screened in our cohort (only 9/80).
The majority of recruits were adults (n = 49) who were
initially investigated before SCN1A testing was available.
Furthermore, in contrast to paediatric settings, the sig-
nificance of SCN1A mutations for adult patients is often
neglected [66], usually because key elements of early his-
tory (e.g. age of onset, initial seizure types) are not avail-
able. We therefore selected a group of patients with
early-onset epilepsy for SCN1A sequencing. Of the 38
patients with seizure onset before 12 months, 6 had pre-
viously had normal testing for SCN1A while 3 others
had pathogenic CNVs. Fifteen of the remaining 29 pa-
tients were prioritized for testing based on clinical fea-
tures (e.g. a history of myoclonic or febrile seizures).
This found 4 pathogenic SCN1A mutations (Table 3).
All four patients had seizure onset in early infancy
(6 months or before) and ongoing seizures despite anti-
convulsant therapy. Three of the mutations were
missense mutations. The fourth was a 4 base duplication
leading to a frameshift early in the gene. In silico analysis
indicated the missense mutations were all deleterious
changes affecting conserved residues (Table 3). One mis-
sense mutation segregated with epilepsy and ID pheno-
types in the patient’s family (the proband’s two affected
siblings and their mildly-affected mother) the others
were all de novo. In combination with the array data
these results indicate that at least 6/80 (7 %) of our
cohort had SCN1A-related seizure disorders.
Conclusions
We have reported the range of rare CNVs found in a
series of 80 Welsh patients with childhood-onset epi-
lepsy and ID/DD. We identified clearly or likely patho-
genic CNVs in 7 (8.8 %) of the patients including 5
rare de novo deletions. Our results highlight key genes
for brain development including drawing attention to
SCN1A mutations in adults with early-onset pharma-
coresistant epilepsy and ID. Our results contribute
additional phenotypic descriptions for these rare gen-
omic disorders and support the use of molecular
cytogenetic analysis in the genetic evaluation of pa-
tients with ID/DD and epilepsy.
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